IL6 and COVID-19: Besides the drug’s ability to inhibit the aforementioned virus, COVID-19 patients might benefit the most from its potential to selectively regulate pro-inflammatory cytokines like IL-6, which has been considered as a prognostic marker for mortality among the same (Gibbs et al., 2012; Liu et al., 2020).